Sanofi : completes Principia Biopharma Inc. acquisition (2024)
Real-time Euronext Paris
Other stock markets
10:02:15 2024-04-22 EDT
5-day change
1st Jan Change
86.98 EUR
+0.10%
-0.50%
-3.06%
09:28am
SANOFI : Gets a Buy rating from UBS
ZD
04-19
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
September 28, 2020 at 09:31 am
Share
Sanofi completes Principia Biopharma Inc. acquisition
*Principia Biopharma Inc. is now a wholly owned subsidiary of Sanofi
PARIS – September 28, 2020 – Sanofi announced today the successful completion of its acquisition of Principia Biopharma Inc. (“Principia”) for $100 per share in cash.
“The Principia acquisition further strengthens our core areas of autoimmune and allergic diseases, giving us full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to further develop,” said Paul Hudson, Sanofi Chief Executive Officer. “The Principia integration into Sanofi augments our small molecule research capabilities as we look to maintain leadership in the discovery and development of oral medicines for serious illnesses.”
The tender offer for all of the outstanding shares of Principia common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Friday, September 25, 2020. The minimum tender condition and all of the other conditions to the offer have been satisfied and on September 28, 2020, Sanofi and its wholly owned subsidiary Kortex Acquisition Corp. (“Purchaser”), accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.
Following its acceptance of the tendered shares, Sanofi completed its acquisition of Principia through the merger of Purchaser with and into Principia, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Principia continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.
In connection with the merger, all Principia shares not validly tendered in the tender offer have been converted into the right to receive the same $100 per share in cash, without interest thereon and net of any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. Principia common stock will cease to be traded on the NASDAQ Global Select Stock Market.
Evercore acted as financial advisor to Sanofi and Weil, Gotshal & Manges LLP acted as its legal counsel. Centerview Partners LLC and BofA Securities, Inc. acted as financial advisors to Principia and Cooley LLP acted as its legal counsel.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life
Media Relations Contact Ashleigh Koss Tel.: +1 908-205-2572 ashleigh.koss@sanofi.com
Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton
Investor Relations Contacts North America
Felix Lauscher Fara Berkowitz Suzanne Greco
IR main line Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com https://www.sanofi.com/en/investors/contact
Forward-Looking Statements This communication contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will be” and similar expressions. Although Sanofi’s and Principia’s management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi and Principia, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to the successful integration of Sanofi and Principia, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company, and the possibility that, if Sanofi does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Sanofi’s shares could decline, as well as other risks related Sanofi’s and Principia’s respective business, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA or the EMA, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and to complete related transactions and/or obtain regulatory clearances, risks associated with Sanofi’s and Principia’s intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Sanofi and Principia and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Sanofi’s and Principia’s employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Sanofi and Principia. This situation is changing rapidly and additional impacts may arise of which Sanofi and Principia are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Sanofi’s consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the “SEC”) and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019, and the current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K filed by Principia with the SEC. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Sanofi and Principia do not undertake any obligation to update or revise any forward-looking information or statements.
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Sector Update: Health Care
MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely
MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely
MT
Sanofi to overhaul US operations of vaccines, cut jobs
RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
MT
SANOFI : JP Morgan reiterates its Neutral rating
ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger
CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets
MT
BeiGene to Award Shares Worth $15 Million to 11 Directors
MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial
MT
Sanofi: new positive phase II results in MS
CF
IDT Australia Signs Master Service Agreement with Sanofi
MT
Sanofi: progress in hematology trial
CF
Innate Pharma: progress in hematology trial
CF
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says
DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs
MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts
RE
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
DJ
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate
MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
CI
Sanofi Launches Rabies Vaccine in the UK
MT
Chart Sanofi
More charts
Company Profile
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;- consumer health products (12%).At the end of 2023, the group had 54 production sites throughout the world.Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
Pharmaceuticals
Calendar
2024-04-25 - Q1 2024 Earnings Release
Related indices
CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)
More about the company
Income Statement Evolution
More financial data
Analysis / Opinion
SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet February 01, 2024 at 11:26 am
Sanofi Sees Trend for Years of Steady Growth: CFO February 03, 2023 at 03:56 pm
More Strategies
Ratings for Sanofi
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
86.89EUR
Average target price
107.5EUR
Spread / Average Target
+23.71%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
Sector Other Pharmaceuticals
1st Jan change
Capi.
SANOFI
-3.06%
116B
ELI LILLY AND COMPANY
+25.42%
654B
NOVO NORDISK A/S
+24.07%
552B
-5.86%
356B
+16.14%
319B
ABBVIE INC.
+8.08%
295B
ASTRAZENECA PLC
+5.91%
211B
NOVARTIS AG
+2.06%
206B
ROCHE HOLDING AG
-7.85%
197B
PFIZER, INC.
-9.92%
147B
Other Pharmaceuticals
Stock Market
Equities
SAN Stock
News Sanofi
Sanofi : completes Principia Biopharma Inc. acquisition
Introduction: My name is Allyn Kozey, I am a outstanding, colorful, adventurous, encouraging, zealous, tender, helpful person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.